Table 5 Association between IGFBP3 mRNA expression and breast cancer survival

Age at diagnosis

   28–39 years

68

16

1.0 (reference)

21

1.0 (reference)

   40–49 years

264

48

0.8 (0.4–1.3)

59

0.7 (0.4–1.1)

   50–59 years

136

37

1.2 (0.6–2.1)

44

1.0 (0.6–1.7)

   60–64 years

53

10

0.7 (0.3–1.6)

12

0.7 (0.3–1.4)

TNM stage

   0, I

124

8

1.0 (reference)

13

1.0 (reference)

   IIa

208

39

2.6 (1.3–5.2)

51

2.4 (1.3–4.2)

   IIb

132

35

3.9 (1.9–7.8)

39

2.8 (1.6–5.1)

   III, IV

49

27

9.8 (4.7–20.3)

31

8.5 (4.6–15.7)

IGFBP3 (all subjects)^a

   T1

173

37

1.0 (reference)

44

1.0 (reference)

   T2

174

43

1.2 (0.7–1.8)

55

1.3 (0.9–2.0)

   T3

174

31

0.9 (0.5–1.4)

37

0.9 (0.6–1.4)

p for trend

0.596

0.715

IGFBP3 (excluding stage IV cases)^a

   T1

172

37

1.0 (reference)

44

1.0 (reference)

   T2

171

42

1.1 (0.7–1.9)

53

1.2 (0.8–1.9)

   T3

170

30

0.9 (0.5–1.4)

37

0.9 (0.6–1.4)

p for trend

0.591

0.777